Donor vaccine could shield transplant patients from common virus
NCT ID NCT06059391
First seen Mar 11, 2026 · Last updated Jun 22, 2026 · Updated 13 times
Summary
This phase 2 trial tests a vaccine called CMV-MVA Triplex given to stem cell donors. The goal is to boost the donor's immunity against cytomegalovirus (CMV) so that when their stem cells are transplanted into a patient with blood cancer, the patient inherits that protection. The study involves 216 donor-recipient pairs and aims to prevent CMV infection, a common and serious complication after transplant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
DFCI/BWH Brigham and Women's Hospital
RECRUITINGBoston, Massachusetts, 02115, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Northside Hospital
RECRUITINGAtlanta, Georgia, 30342, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CMV-MVA Triplex vaccine
What this could lead to
If it works, this vaccine could help prevent dangerous CMV infections in stem cell transplant patients by giving them immunity from their donor.
What could go wrong
This is a mid-stage trial with only 216 participants, so results may not apply to everyone. The vaccine is given to donors, not patients, and its effectiveness is still unproven.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.